title: Bone mineral status, bone turnover markers and vitamin D status in children with congenital adrenal hyperplasia.
abstract: Treatment of congenital adrenal hyperplasia (CAH) consists of lifelong glucocorticoid therapy (GT), and long-term GT may cause osteoporosis. We aim to analyse bone mineral status (BMS) and bone turnover markers in children with CAH. Methods. The study included 17 patients with CAH (mean age ± SD; 7.96± 3.58 years, range 3-13.3 years) and age-matched controls. Bone metabolism rate, vitamin D status and BMS were analyzed. Alterations in bone metabolism rate were prospectively evaluated. Results. We found that BMS Z score did not differ between the patients and control group. Vitamin D deficiency is common in groups, and osteocalcin, β crosslaps and PTH was higher in patients than the healthy controls (5.3±3.4 vs. 3.2±1.8, P=0.036 and 2.19±1.59 vs. 1.27±0.99, P=0.049, 38.1±18.3 vs. 22.7±13.3, P=0.009, respectively). BMS Z score was only positively correlated with 17 OHP levels (r=0.462, P=0.05) and height SD Z scores (r=0.477, P=0.049). Seasonal measurements of vitamin D status, PTH levels and bone turnover markers exhibit that PTH levels, osteocalcin and β crosslaps increase in response to low vitamin D levels. Conclusion. Children with CAH have BMS values that are not different age-matched controls. Vitamin D status should be systematically measured in CAH patients, and supplementation should be recommended in patients with low vitamin D levels.
authors: Department of Pediatric Endocrinology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
authors: A
authors: A
authors: Okten
authors: M
authors: M
authors: Cakir
authors: M
authors: M
authors: Makuloglu
mesh_terms: D015502:Absorptiometry, Photon; D000293:Adolescent; D000312:Adrenal Hyperplasia, Congenital / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D000465:Algorithms; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000097:blood*; D016723:Bone Remodeling; D001842:Bone and Bones / Q000378:metabolism; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003094:Collagen / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D015675:Osteocalcin / Q000097:blood*; D010024:Osteoporosis / Q000139:chemically induced; D010281:Parathyroid Hormone / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood; D011446:Prospective Studies; D014807:Vitamin D / Q000008:administration & dosage / Q000097:blood*; D014808:Vitamin D Deficiency / Q000188:drug therapy
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D005938:Glucocorticoids; D010281:Parathyroid Hormone; D010446:Peptide Fragments; C110762:glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine; D015675:Osteocalcin; D014807:Vitamin D; D003094:Collagen